The Sarcoma Molecular Biology Laboratory (SMBL), under the direction of Zhenfeng Duan, MD, PhD and Francis J. Hornicek, MD, PhD, is working on understand the mechanisms of multidrug resistance, identification of small molecules and targets to reverse drug resistance, and characterization of molecular mechanisms governing growth, proliferation of human sarcoma cells.

The overall objectives of our laboratory are to explore biological mechanisms of tumors arising in bone and other tissues.  One of the major focuses of the lab is to elucidate the mechanisms of the development of drug resistance in cancer.  Previously, we have found multidrug resistance could be partially reversed by siRNA targeting of ABCB1 (MDR1) or by combination of nanoparticles with chemotherapy drug.  Recently, we have identified two small molecules that can overcome drug resistance in vitro.  Another significant aim of our research is to define the essential kinases that are responsible for proliferation and survival of human sarcoma cells.  In addition, translational research into new treatment options for sarcoma patients has been undertaken. Continued collaboration with other institutions and pharmaceutical companies has provided the foundation for evaluation of new drug development.  Many of these drugs are derived from marine sources and their corresponding biochemical structures are quite complex.  The Sarcoma Molecular Biology Laboratory has published articles pertaining to multiple drug resistance in human cancer. Research projects on sarcoma biology have received funding from a variety of sources including NIH, foundations, corporate sponsors, and benefactors.

The sarcoma research group at the MGH includes investigators from multiple disciplines, as does the clinical group.  We hope to continue research expansion and further collaboration within the Harvard community.